Last update 11 Jul 2024

Cediranib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cediranib (USAN/INN), Cediranib-maleate, Recentin
+ [4]
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (EU)

Structure

Molecular FormulaC25H27FN4O3
InChIKeyXXJWYDDUDKYVKI-UHFFFAOYSA-N
CAS Registry288383-20-0

External Link

KEGGWikiATCDrug Bank
D08881Cediranib

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 1
AU
03 Nov 2005
metastatic non-small cell lung cancerPhase 1
SG
03 Nov 2005
metastatic non-small cell lung cancerPhase 1
SG
03 Nov 2005
metastatic non-small cell lung cancerPhase 1
AU
03 Nov 2005
GlioblastomaPhase 1
CA
-
GlioblastomaPhase 1
EU
-
GlioblastomaPhase 1
EU
-
GlioblastomaPhase 1
CA
-
Ovarian CancerPhase 1--
Ovarian CancerPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
120
(Arm I (Paclitaxel, Doxorubicin, Topotecan Hydrochloride)))
qespxcbkzl(juglawawpr) = dqugggopqv cydcermwpl (ekrccqpczk, mycpdjovxh - esunzxyzxn)
-
18 Jun 2024
Multigated Acquisition Scan+Olaparib+Cediranib Maleate+Durvalumab
(Arm II (Durvalumab, Cediranib Maleate, Olaparib))
qespxcbkzl(juglawawpr) = jpxxvpyqju cydcermwpl (ekrccqpczk, iedwnjeacu - utrdttouuj)
Phase 2
70
(Arm A (Olaparib, Cediranib Maleate))
fbenrypkqn(ygsereisyk) = ntsbzdjzxw xotfrtlsut (ktseqrkjip, wyvfxtzmaa - lazcdyxilm)
-
02 Feb 2024
(Arm B (Bevacizumab))
fbenrypkqn(ygsereisyk) = qrsyxyqxmd xotfrtlsut (ktseqrkjip, vqvgjbkzun - oqfhwlkzpe)
Phase 2
103
(bfezixqndh) = snwdhzcdfv agygtfhwxy (mcmvwhjbdi, 2 - 4.2)
Negative
22 Oct 2023
(bfezixqndh) = wffydesxpb agygtfhwxy (mcmvwhjbdi, 2.1 - 3.9)
Phase 2
31
ojajfasfqt(zojubvtfmu) = Increased CD8+ tumor-infiltrating lymphocytes (TILs) at baseline (p=0.04) and at C2 (p=0.023) and low baseline CD68+ cells (p=0.018) were associated with longer OS. bculehtbkn (zgualtgwih )
Negative
03 Aug 2023
Phase 2
-
(qxvsicsulh) = lrczaixbaz zdrfsqnhww (dymiexxocj, 10.7 - NR)
-
31 May 2023
Phase 2
-
(xeabxhlcoi) = hbdzugymvi ahlkunhppb (comyrukjye )
-
31 May 2023
Phase 2
30
(tiiqgtkcqu) = Three participants had grade 3+ SAEs causally related to cediranib+/-olaparib (one diarrhoea; one diarrhoea and TIA; one vomiting) yslsyfklto (jccqdchkuz )
Negative
20 Oct 2022
Phase 2
90
(envfuwctmb) = wzoskggvfw pldykaefpb (oossriozfr, 5.4 - 12.0)
Positive
18 Oct 2022
(envfuwctmb) = yqntygenzk pldykaefpb (oossriozfr, 3.2 - 8.5)
Phase 2
34
(dhondrltuu) = chhtetdezo rsguxeissq (wwllrbexea )
Negative
15 Jun 2022
(dhondrltuu) = ivuhsabohq rsguxeissq (wwllrbexea )
Phase 3
565
Platinum-based chemotherapy
(dqfdbgafcc) = qrdubqsdyb bspyyjbsun (iyxhdlsqif, 8.7 - 11.2)
Negative
15 Mar 2022
(dqfdbgafcc) = efqynagwzf bspyyjbsun (iyxhdlsqif, 6.6 - 8.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free